Anti-Mouse CD8a Monoclonal Antibodies for Flow Cytometry

PA007498.r2b: Recombinant Anti-mouse CD8a Monoclonal Antibody (Clone: 2.43), Rat IgG2b Kappa

Recombinant Rat IgG2b Monoclonal Antibody. 
Clone: 2.43.
Isotype:  Rat IgG2b Kappa.
Source: The anti-mouse CD8a monoclonal antibody (clone: 2.43) was produced in mammalian cells.
Conjugation: Non-conjugated.
Specificity/Sensitivity: The recombinant 2.43 antibody specifically binds to mouse CD8a protein.
Applications: Flow cytometry (FC), and Immunohistochemistry - Frozen (IHC-F). 
Form of Antibody: 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Purity: >95% by SDS-PAGE under reducing conditions.

PA007498.h1Fs: Recombinant Anti-mouse CD8a Monoclonal Antibody (Clone: 2.43), Human IgG1 Fc Silent Kappa

Recombinant Human IgG1 Monoclonal Antibody with Fc silent mutation. 
Clone: 2.43.
Isotype: Human IgG1 kappa.
Source: The anti-mouse CD8a monoclonal antibody (clone: 2.43) was produced in mammalian cells.
Conjugation: Non-conjugated.
Specificity/Sensitivity: The recombinant 2.43 antibody specifically binds to mouse CD8a protein.
Applications: Flow cytometry (FC), and Immunohistochemistry - Frozen (IHC-F). 
Form of Antibody: 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Purity: >95% by SDS-PAGE under reducing conditions.

PA007726.h1Fs-b: Biotinylated Recombinant Anti-mouse CD8a Monoclonal Antibody (Clone: 2.43), Human IgG1 Fc Silent Kappa

Recombinant human IgG1 monoclonal antibody with site-directed biotinylation through the Avi tag at the C-terminus of the antibody heavy chain.
Clone: 2.43.
Isotype: Human IgG1 Fc Silent Kappa.
Source: The site-directed biotinylated anti-mouse CD8a monoclonal antibody (clone: 2.43) was produced in mammalian cells.
Conjugation: Biotin-conjugated.
Specificity/Sensitivity: The site-directed biotinylated recombinant 2.43 antibody specifically binds to mouse CD8a protein.
Applications: Flow cytometry (FC) with various dye conjugation through streptavidin; conjugation to streptavidin agarose beads or streptavidin magnetic beads.
Form of Antibody: 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Purity: >95% by SDS-PAGE under reducing conditions.

Shipping: The 2.43 antibody is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.

Background

The rat anti-mouse CD8a monoclonal antibody 2.43 (rat IgG2b kappa) reacts with the mouse CD8a protein (T-cell surface glycoprotein CD8 alpha chain) encoded by the mouse CD8A gene that encodes the CD8a chain of the dimeric CD8 protein. The mouse CD8 protein is primarily responsible for cell-mediated immune defense and T-cell development. CD8A has been widely reported as a potential prognosis and diagnostic marker for several diseases, such as inflammatory disorders and tumors. It was shown that the anti-mouse CD8a rat monoclonal antibody (clone number: 2.43) can be used for depleting activity in vivo.
Our recombinant 2.43 antibodies have a part (variable regions) or complete amino acid sequences of the rat anti-mouse CD8a monoclonal antibody (hybridoma clone name or number: 2.43).

References of anti-mouse CD8a antibody for Flow Cytometry (2.43):

1、Circulating neutralizing antibodies and SARS-CoV-2 variant replication following postvaccination infections.
Garcia-Knight, M. A., et al. JCI Insight. 2025 Mar;10(5):e185953. doi: 10.1172/jci.insight.185953. PMID: 40059831
Per log10 increase in Delta-targeting baseline NAb IC50, maximum viral load was reduced –2.43 (2.43 antibody) (95% CI: –3.76, –1.11) log10 nucleocapsid copies, and infectious viral shedding was reduced –2.79 (95% CI: –4.99, –0.60) days. ...Our findings show that, following PVI (in people vaccinated with ancestral spike antigens), higher baseline NAb titers are associated with accelerated viral clearance dynamics following infections with Delta variants, and we provide robust estimations to help quantify this effect. ...This suggests that NAbs generated through first-generation vaccines are limited in their ability to target conserved epitopes in the spike protein of Omicron variants and support the use of booster vaccination with updated antigens that may further broaden the NAb response. ...It remains to be seen whether enhancing baseline neutralizing antibody (anti-mouse CD8a antibody) (NAb) titers through updated vaccine antigens can reestablish the correlation with viral shedding outcomes in primary viral infections (PVI) involving current circulating variants. ...Baseline NAb titers targeting the infecting variant for each participant (except those with BA.5 infections for which response against BA.2 are shown) were higher in those who had received vaccine booster doses compared with those who received a primary series (P < 0.05).
Tags: anti-mouse CD8a antibody; 2.43 antibody

2、Combination of omalizumab with allergen immunotherapy versus immunotherapy alone for allergic diseases: A meta-analysis of randomized controlled trials.
Zhang, Y.-Y., et al. International Forum of Allergy & Rhinology. 2024 Apr;14(4):794-806. doi: 10.1002/alr.23268. PMID: 37715592
According to a pooled analysis, omalizumab + AIT significantly increased the number of patients achieving the target maintenance dose (TMD) and sustained unresponsiveness (SU) to allergens (odds ratio [OR] = 2.43 (anti-mouse CD8a 2.43 antibody); 95% CI: 1.33–4.44; p = 0.004; I2 = 35%, and OR = 6.77; 95% CI: 2.10–21.80; p = 0.001; I2 = 36%, respectively). ...The monoclonal anti-IgE antibody (omalizumab) and AIT have complementary actions. ...However, no consensus has been reached on whether their combination could exert superior efficacy and safety. ...Allergen immunotherapy (AIT)-associated adverse events (AEs) limit its usage in the management of allergic diseases. ...The MEDLINE/PubMed, Embase, Scopus and Cochrane Library databases were searched to identify randomized control trials (RCTs) reporting the outcomes of omalizumab combined with AIT (omalizumab + AIT) versus AIT alone.
Tags: anti-mouse CD8a 2.43 antibody; anti-mouse CD8a 2.43 in vivo

For more references about anti-mouse CD8a antibody for Flow Cytometry (2.43) please contact our scientific support team with message@sydlabs.com.

Syd Labs provides the following in vivo grade recombinant anti-mouse CD8 monoclonal antibodies:
Recombinant Anti-mouse CD8a monoclonal antibody (Clone: 2.43)
Recombinant Anti-mouse CD8a monoclonal antibody (Clone: YTS 169.4)
Recombinant Anti-mouse CD8a monoclonal antibody (Clone: YTS 105.18)
Recombinant Anti-mouse CD8a monoclonal antibody (Clone: 53-6.72)
Recombinant Anti-mouse CD8b monoclonal antibody (Clone: YTS 156.7)
Recombinant Anti-mouse CD8 (Lyt 2.1) monoclonal antibody (Clone: 116-13.1)

Syd Labs provides the following in vivo grade recombinant anti-human CD8 monoclonal antibodies:
Recombinant Anti-human CD8a monoclonal antibody (Clone: OKT8)

Syd Labs provides the following recombinant anti-mouse CD8 monoclonal antibodies for flow cytometry:
Recombinant Anti-mouse CD8a monoclonal antibody (Clone: 2.43) for flow cytometry
Recombinant Anti-mouse CD8a monoclonal antibody (Clone: YTS 169.4) for flow cytometry
Recombinant Anti-mouse CD8a monoclonal antibody (Clone: YTS 105.18) for flow cytometry
Recombinant Anti-mouse CD8b monoclonal antibody (Clone: YTS 156.7) for flow cytometry

Syd Labs provides the following recombinant anti-human CD8 monoclonal antibodies for flow cytometry:
Recombinant Anti-human CD8a monoclonal antibody (Clone: OKT8) for flow cytometry